Pharmaceutical Industrial Policy Committee Study Group on Extending Healthy Life Expectancy and Driving Economic Growth ～Research and Proposal on the Contribution of the Pharmaceutical Industry to Extending Healthy Life Expectancy and Driving Economic Growth
Reports
Data in Charts 5 and 6 of the report published on 4/20 were incorrect. The data has now been corrected in the published version. We apologize for any inconvenience caused.
Overview
We are pleased to announce the launch of the “Study Group on Extending Healthy Life Expectancy and Driving Economic Growth” — Toward the Future of the Pharmaceutical Industry — (hereinafter referred to as “this Study Group”).
There is a mounting number of social issues related to “health” and “the economy.” In the healthcare sector in particular, there are various challenges, such as the growing demand for medical care due to an aging population, problems with healthcare delivery systems resulting from population decline, and future financial concerns.
This research group has invited experts who are leading academic research on the overall direction of healthcare to participate. We expect them to discuss, from anWe also expect them to widely disseminate their views on the direction the pharmaceutical industry should take, based on evaluated and analyzed evidence.
The Japan Pharmaceutical Manufacturers Association (Chairman: Yasushi Okada; hereinafter “JPMA”) will fully support the discussions within this study group and will publish the evidence and other information generated by the group on its website.
For further information, please contact
JPMA Secretariat, Policy Division